ArticleJournal for immunotherapy of cancer2016

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.

Jared R Lowe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.